News + Resources
Keep up with the latest
Featured
Recent
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
All Stories
News
FDA approves CRISPR–Cas9 therapy for sickle cell disease
December 8, 2023
ASBMB Today
Read Now
Press
FDA approves CRISPR–Cas9 therapy for sickle cell disease
December 8, 2023
ASBMB Today
Read Now
News
A decade later, biotech’s CRISPR revolution is still going strong
October 11, 2023
Biopharma Dive
Read Now
Press
A decade later, biotech’s CRISPR revolution is still going strong
October 11, 2023
Biopharma Dive
Read Now
News
Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics
October 6, 2023
San Francisco Business Times
Read Now
Press
Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics
October 6, 2023
San Francisco Business Times
Read Now
News
Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners
July 20, 2023
Wall Street Journal
Read Now
Press
Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners
July 20, 2023
Wall Street Journal
Read Now